Skip to content

To compare the efficacy and safety of two different analgesic formulations in the management of dental pain following tooth extraction.

A randomized open label comparative study evaluating the efficacy and tolerability of diclofenac (50mg) + paracetamol (500mg) FDC vs. ibuprofen (400mg) in the management of dental pain following impacted third molar extraction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/091/000169
Enrollment
150
Registered
2011-02-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dental Pain following tooth extraction

Interventions

Intervention1: Fixed Dose of Diclofenac 50mg plus Paracetamol 500 mg: One Tablet Twice a day Control Intervention1: Ibuprofen 400 mg: One Tablet Three Times A day

Sponsors

Troikaa Pharmaceuticals Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients needing extraction for impacted third molars under local anesthesia. 2.Between the ages of 18 to 45 years. 3. In general good health- American Society of Anesthesiologists (ASA) status I or II (healthy subjects based upon criteria for safe administration of out-patient conscious sedation). 4. Willing to undergo observation period for three hours post-extraction. 5. Willing for telephonic follow up. 6. Ability to complete a 10 cm visual analog scale and a category scale every 30 minutes for the first 3 postoperative hours.

Exclusion criteria

Exclusion criteria: 1. Surgical Time in excess of 45 minutes. 2. Patients with known hypersensitivity to any of the study drugs. 3. Patients with any contraindication to the study drugs. 4. Patients who are pregnant or nursing. 5. Patients with history of peptic ulcers and/or GI bleeding. 6. Patients who have significant psychiatric history. 7. Patients with severe kidney/ liver disease. 8. Patients who are taking any of the following drugs: ACE inhibitor; potassium sparing diuretics; aspirin on a near daily basis; coumarin or other blood thinners. 9. Unusual surgical difficulty (determined from panoramic radiograph or during the actual surgery). 10. Patients who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use) within 4 weeks prior to randomization. 11. Patient known or, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency, or psychotic state).

Design outcomes

Secondary

MeasureTime frame
Pain intensity difference at 8 hours (PID8), Time to maximum PID (tmaxPAID), Pain relief scores at 24, 48 hours (PR24, PR48) and on day 4 (PRday4), Global efficacy by patients and investigator, Rescue analgesia requirement.Timepoint: The pain intensity shall be assessed at baseline, 30min, 60min, 2hrs, 4 hrs, 6 hrs, 8 hrs, 24 hrs, 48 hrs and on 4th post extraction day.

Primary

MeasureTime frame
Time to onset of analgesia, Time to Maximum Pain relief (tMaxPR), Pain relief at 8 hrs (PR8).Timepoint: After Administration of Study Medication.

Countries

India

Contacts

Public ContactDr Sanjay Maroo

Medical Services.

medicalservices@troikaapharma.com917926856242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026